Development and evaluation of the Parkinson Psychosis Questionnaire: A screening-instrument for the early diagnosis of drug-induced psychosis in Parkinson's disease

Journal of Neurology

Volumn 252, Issue 9, 2005, Pages 1060-1066

  Brandstaedter, D ^a   Spieker, S ^a   Ulm, G ^b   Siebert, U ^c,d   Eichhorn, T E ^a   Krieg, J C ^a   Oertel, W H ^a   Eggert, K ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b Paracelsus Elena Klinik   (Germany)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d HARVARD CENTER FOR RISK ANALYSIS   (United States)

Author keywords

BPRS; Drug induced psychosis; Parkinson Psychosis Questionnaire; Parkinson's disease; SCID; Screening instrument

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; BUDIPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; SELEGILINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DELUSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; HALLUCINATION; HUMAN; ILLUSION; INTERVIEW; MALE; MONITORING; ORIENTATION; PARKINSON DISEASE; PARKINSONISM; PREDICTION; PRIORITY JOURNAL; PSYCHOSIS; QUESTIONNAIRE; RATING SCALE; SCREENING; SENSITIVITY ANALYSIS; SLEEP DISORDER; VALIDATION PROCESS;

ANTIPARKINSON AGENTS; FEMALE; HUMANS; MALE; PARKINSONIAN DISORDERS; PSYCHOSES, SUBSTANCE-INDUCED; QUESTIONNAIRES; SENSITIVITY AND SPECIFICITY;

EID: 25144486661     PISSN: 03405354     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00415-005-0816-x     Document Type: Article

References (28)

1. Melamed E, Friedberg G, Zoldan J (1999) Psychosis-impact on the patient and family. Neurology 52(Suppl):14-16
2. Carter JH, Stewart BJ, Archold PG (1998) Living with a person who has Parkinson's disease: the spouse's perspective by stage of disease. Mov Disord 13:20-28
3. Friedman JH (1991) The management of levodopa psychosis. Clin Neuropharmacol 14:283-295
4. Goetz CG, Stebbins GT (1995) Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology 45:669-671
5. Goetz CG, Stebbins GT (1993) Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 43:2227-2229
6. Doraiswamy M, Martin W, Metz A, Deveaugh-Geiss J (1995) Psychosis in Parkinson's disease: Diagnosis and treatment. Prog Neuro-Psychopharmacol Biol Psychiatry 19:835-846
7. Aarsland D, Laarsen JP, Cummings JL, Laake K (1999) Prevalence and clinical correlates of psychotic symptoms in Parkinson's disease. A community-based study. Arch Neurol 56:595-601
8. Wolters EC (1999) Dopaminomimetic psychosis in Parkinson's disease patients. Neurology 52(Suppl):10-13
9. Cummings JL (1991) Behavioral complications of drug treatment of Parkinson patients. J Am Geriat Soc 39:708-716
10. Moskovitz C, Moses H, Klawans HL (1978) Levodopa-induced psychosis: A kindling phenomenon. Am J Psychiatry 135:669-675
11. Pappert EJ, Goetz CG, Niederman FG, Raman R, Leurgans S (1999) Hallucinations, sleep fragmentation and altered dream phenomena in Parkinson's disease. Mov Disord 14:117-121
12. Nausieda PA, Weiner WJ, Kaplan LR, Weber A (1982) Sleep disruption in the course of chronic levodopa therapy: an early feature of levodopa psychosis. Clin Neuropharmacol 5:183-195
13. Fenelon G, Mahieux F, Huon R, Ziegler M (2000) Hallucinations in Parkinson's disease - prevalence, phenomenology and risk factors. Brain 123:733-745
14. Friedman JH, Factor SA (2000) Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 15:201-211
15. Friedberg G, Zoldan J, Weizman A, Melamed E (1998) Parkinson psychosis Rating Scale: A practical instrument for grading psychosis in Parkinson's disease. Clin Neuropharmacol 21:28-284
16. Sanchez-Ramos JR, Ortoll R, Paulson GW (1996) Visual hallucinations associated with Parkinson's disease. Arch Neurol 53:1265-1268
17. Wittchen HU, Wunderlich U, Gruschwitz S, Zaudig M (1997) SKID - Strukturiertes klinisches Interview für DSM IV (deutschsprachige, erweiterte Bearbeitung der amerikanischen Original-version SCID). Hogrefe Verlag, München
18. Overall JE, Gorham DR (1988) Introduction - the Brief Psychiatric Rating Scale (BPRS): recent developments. Psychopharmacol Bull 21:97-99
19. Hoehn M, Yahr M (1967) Parkinsonism: onset, progression and mortality. Neurology 17:427-442
20. Lang AET, Fahn S (1989) Assessment of Parkinson's disease. In: Munsat TL (ed) Quantification of neurologic deficit. Butterworths, Boston, pp 285-309
21. Folstein MF, Folstein SE, McHugh PR (1975) Mini-Mental State. A practical method for grading the cognitive state of patients for clinicians. J Psychiatric Res 12:189-198
22. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease. A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181-184
23. Gilman S, Low PA, Quinn N, et al. (1999) Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 163:94-98
24. Goetz CG, Leurgans S, Pappert EJ, Raman R, Stemer AB (2001) Prospective longitudinal assessment of hallucinations in Parkinson's disease. Neurology 57:2078-2082
25. Brandstaedter D, Lotze J, Spieker S, Ulm G, Oertel WH (2002) Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson's disease. Neurology 58:160-161
26. McKeith IG, Galasko D, Kosaka K, et al. (1996) Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47:673-678
27. Cronbach LJ (1951) Coefficient alpha and the internal structure of tests. Psychometrika 16:297-333
28. Bland JM, Altman DG (1997) Cronbach's alpha. BMJ 314:572